Searched for
ASTRAZENECA OXFORD
AstraZeneca jab uncertainty will hit Oxford BioMedica’s revenueIn a recent report, Oxford Biomedica warned that uncertainty surrounding AstraZeneca’s Covid-19 contract will bring reduction in earnings t...- EU regulator advices against second AstraZeneca shot in those with blood clotsThe advice for healthcare professionals was provided by the European Medicines Agency (EMA) as part of an ongoing review into rare, but sev...
- Two AstraZeneca COVID shots could be 85-90% effective, UK real-world data suggestPHE said the preliminary findings were the first of its kind on the effectiveness of two doses of AstraZeneca in a real-world setting but c...
- UK scientists find higher risk of brain clots from COVID-19 compared with vaccinesA study of 500,000 COVID-19 patients found CVST had occurred at a rate of 39 people out of a million following infection, researchers said....
- Sri Lanka temporarily suspends COVID-19 jabs due to delay in securing vaccines from SII: MinisterSri Lanka launched its inoculation programme in late January when India gifted 500,000 doses of Oxford-AstraZeneca. Till Thursday 913,219 p...
- AstraZeneca says US trial data shows vaccine 79% effectiveThe U.S. study comprised 30,000 volunteers, 20,000 of whom were given the vaccine while the rest got dummy shots. The results were announed...
- Oxford study indicates AstraZeneca effective against Brazil variant, source saysThe data indicates that the vaccine will not need to be modified in order to protect against the variant, which is believed to have origina...
- AstraZeneca, Oxford expect 'next generation' COVID-19 vaccine to tackle variants by autumn - executiveAsked when AstraZeneca could produce a next generation vaccine to tackle new variants, AstraZeneca research chief Mene Pangalos said "as ra...
- Britain approves AstraZeneca/Oxford COVID-19 vaccineRegulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the resul...
- AstraZeneca's Covid-19 vaccine has a 'winning formula': Chief executive Pascal SoriotThe UK government announced on December 23 that the developers of the Oxford AstraZeneca vaccine had submitted their data to the Medicines ...
- Serum Institute of India ready for Covid-19 vaccine rollout: OfficialSII has already manufactured around 50 million doses of its Covid vaccine called Covishield, which is based on the technology from drugmake...
- Oxford/AstraZeneca in ‘mix-match' COVID-19 vaccine trial with Russia's SputnikThe two sets of experts are to join forces to explore if a combination of the two jabs, both using a benign virus called adenovirus, could ...
- Oxford-Astra COVID-19 vaccine shows average 70.4% efficacy in pooled studyAstraZeneca Chief Executive Officer Pascal Soriot said the drugmaker had begun submitting data to regulatory authorities around the world t...
- After varied efficacy data, AstraZeneca to conduct fresh clinical trials of COVID-19 vaccineAstraZeneca/Oxford said this week it would assess why its vaccine candidate generated better efficacy at a lower dose. The statement came a...
- Oxford COVID-19 vaccine produces immune response among elderly and young, AstraZeneca saysA vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people,...
- Will resume COVID-19 vaccine trials after DCGI nod: Serum InstitutePharma giant AstraZeneca on Saturday said that clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the...
- Oxford, AstraZeneca COVID-19 vaccine trials resume days after pauseThe study had been previously stopped in July for several days after a participant who got the vaccine developed neurological symptoms; it ...
- Serum Institute of India officially halts the trial of Astrazeneca-Oxford vaccine in India"We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following DCGI's instructions and wil...
- India trials of COVID-19 vaccine is going on: Serum InstituteLast month, the Drug Controller General of India had granted permission to the Pune-based SII to conduct Phase-II and -III human clinical t...
- Serum Institute of India seeks DCGI permission for phase 2/3 clinical trials of Oxford's COVID 'vaccine'The sources told that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials...
Load More
